84
Participants
Start Date
October 30, 2023
Primary Completion Date
February 23, 2024
Study Completion Date
March 18, 2024
Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)
"2 sprays per nostril of Azelastine 0.15% twice daily.~Total dose of active drug:~1644 mcg azelastine hydrochloride per day"
Treatment B: Placebo (Azelastine 0.15% vehicle) nasal spray
2 sprays per nostril of Placebo twice daily.
Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
"2 sprays per nostril of Ryaltris twice daily.~Total dose of active drug:~200 mcg mometasone furoate and 4800 mcg olopatadine per day"
Cliantha Research, Mississauga
MEDA Pharma GmbH & Co. KG
INDUSTRY